Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888914 | 0.84 | KIF11 (0.41) | KIF11CYP11B1CYP11B2BRD4 | |
| SCHEMBL4596423 | 0.79 | KIF11 (0.47) | KIF11CYP11B1CYP11B2TDP2BRD4 | |
| SCHEMBL14154359 | 0.79 | KIF11 (0.47) | KIF11CYP11B1CYP11B2TDP2BRD4 | |
| Trifluoroacetic Acid SCHEMBL4596431 | 0.74 | KIF11 (0.42) | KIF11TDP2BRD4 | |
| Trifluoroacetic Acid SCHEMBL4595122 | 0.74 | KIF11 (0.42) | KIF11TDP2BRD4 | |
| SCHEMBL4596430 | 0.72 | KIF11 (0.59) | KIF11CYP11B1CYP11B2TDP2MCL1 | |
| SCHEMBL4595242 | 0.70 | KIF11 (0.64) | KIF11CYP11B1CYP11B2TDP2 | |
| SCHEMBL15565139 | 0.69 | KIF11 (0.43) | KIF11TDP2BRD4KMT2A | |
| SCHEMBL4596144 | 0.65 | KIF11 (0.60) | KIF11TDP2KMT2A | |
| SCHEMBL4890890 | 0.65 | KIF11 (0.49) | KIF11TDP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885CYP11B1 780/4885CYP11B2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.